Skip to main content
Fig. 6 | Breast Cancer Research

Fig. 6

From: KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene

Fig. 6

KLF4 expression dictates sensitivity to pharmacological inhibition of EGFR. a MDA-MB-231 and b MDA-MB-468 cells were infected with AdGFP or AdKLF4, and 2 days later, treated with 0–60 μM erlotinib for 3 days. The live cells were counted using trypan blue exclusion assay. Responses were normalized to effects observed with no drug for both AdGFP- and AdKLF4-infected cells. c MCF10A cells were transfected with siNS or siKLF4, and after 1 day, were treated with 0–60 μM erlotinib for 3 days. Cell number was counted, and the relative impact of the drug was normalized for siNS or siKLF4 in the absence of the drug. For each graph, nonlinear regression analysis was performed on IC50 values of control versus experimental group, and each comparison resulted in statistical significance at p < 0.0001. Error bars represent the standard deviation. Experiments were performed three independent times in triplicate

Back to article page